IBDEI0TF ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,13239,2)
;;=^5005907
;;^UTILITY(U,$J,358.3,13240,0)
;;=H40.61X2^^51^632^49
;;^UTILITY(U,$J,358.3,13240,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13240,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Moderate Stage
;;^UTILITY(U,$J,358.3,13240,1,4,0)
;;=4^H40.61X2
;;^UTILITY(U,$J,358.3,13240,2)
;;=^5005908
;;^UTILITY(U,$J,358.3,13241,0)
;;=H40.61X3^^51^632^50
;;^UTILITY(U,$J,358.3,13241,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13241,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Severe Stage
;;^UTILITY(U,$J,358.3,13241,1,4,0)
;;=4^H40.61X3
;;^UTILITY(U,$J,358.3,13241,2)
;;=^5133509
;;^UTILITY(U,$J,358.3,13242,0)
;;=H40.61X4^^51^632^51
;;^UTILITY(U,$J,358.3,13242,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13242,1,3,0)
;;=3^GLU 2nd to Drugs,OD,Indeterminate Stage
;;^UTILITY(U,$J,358.3,13242,1,4,0)
;;=4^H40.61X4
;;^UTILITY(U,$J,358.3,13242,2)
;;=^5005909
;;^UTILITY(U,$J,358.3,13243,0)
;;=H40.813^^51^632^64
;;^UTILITY(U,$J,358.3,13243,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13243,1,3,0)
;;=3^GLC w/ Increased Episcleral Venous Pressure,OU
;;^UTILITY(U,$J,358.3,13243,1,4,0)
;;=4^H40.813
;;^UTILITY(U,$J,358.3,13243,2)
;;=^5005921
;;^UTILITY(U,$J,358.3,13244,0)
;;=H40.811^^51^632^62
;;^UTILITY(U,$J,358.3,13244,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13244,1,3,0)
;;=3^GLC w/ Increased Episcleral Venous Pressure,OD
;;^UTILITY(U,$J,358.3,13244,1,4,0)
;;=4^H40.811
;;^UTILITY(U,$J,358.3,13244,2)
;;=^5005919
;;^UTILITY(U,$J,358.3,13245,0)
;;=H40.812^^51^632^63
;;^UTILITY(U,$J,358.3,13245,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13245,1,3,0)
;;=3^GLC w/ Increased Episcleral Venous Pressure,OS
;;^UTILITY(U,$J,358.3,13245,1,4,0)
;;=4^H40.812
;;^UTILITY(U,$J,358.3,13245,2)
;;=^5005920
;;^UTILITY(U,$J,358.3,13246,0)
;;=H40.823^^51^632^67
;;^UTILITY(U,$J,358.3,13246,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13246,1,3,0)
;;=3^Hypersecretion GLC,OU
;;^UTILITY(U,$J,358.3,13246,1,4,0)
;;=4^H40.823
;;^UTILITY(U,$J,358.3,13246,2)
;;=^5005925
;;^UTILITY(U,$J,358.3,13247,0)
;;=H40.821^^51^632^65
;;^UTILITY(U,$J,358.3,13247,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13247,1,3,0)
;;=3^Hypersecretion GLC,OD
;;^UTILITY(U,$J,358.3,13247,1,4,0)
;;=4^H40.821
;;^UTILITY(U,$J,358.3,13247,2)
;;=^5005923
;;^UTILITY(U,$J,358.3,13248,0)
;;=H40.822^^51^632^66
;;^UTILITY(U,$J,358.3,13248,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13248,1,3,0)
;;=3^Hypersecretion GLC,OS
;;^UTILITY(U,$J,358.3,13248,1,4,0)
;;=4^H40.822
;;^UTILITY(U,$J,358.3,13248,2)
;;=^5005924
;;^UTILITY(U,$J,358.3,13249,0)
;;=H40.43X0^^51^632^27
;;^UTILITY(U,$J,358.3,13249,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13249,1,3,0)
;;=3^Inflam GLC,OU,Stage Unspec
;;^UTILITY(U,$J,358.3,13249,1,4,0)
;;=4^H40.43X0
;;^UTILITY(U,$J,358.3,13249,2)
;;=^5005878
;;^UTILITY(U,$J,358.3,13250,0)
;;=H40.43X1^^51^632^28
;;^UTILITY(U,$J,358.3,13250,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13250,1,3,0)
;;=3^Inflam GLC,OU,Mild Stage
;;^UTILITY(U,$J,358.3,13250,1,4,0)
;;=4^H40.43X1
;;^UTILITY(U,$J,358.3,13250,2)
;;=^5005879
;;^UTILITY(U,$J,358.3,13251,0)
;;=H40.43X2^^51^632^29
;;^UTILITY(U,$J,358.3,13251,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,13251,1,3,0)
;;=3^Inflam GLC,OU,Moderate Stage
;;^UTILITY(U,$J,358.3,13251,1,4,0)
;;=4^H40.43X2
;;^UTILITY(U,$J,358.3,13251,2)
;;=^5005880
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0TF 3759 printed Sep 15, 2024@21:19:39 Page 2
IBDEI0TF ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,13239,2)
+2 ;;=^5005907
+3 ;;^UTILITY(U,$J,358.3,13240,0)
+4 ;;=H40.61X2^^51^632^49
+5 ;;^UTILITY(U,$J,358.3,13240,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,13240,1,3,0)
+8 ;;=3^GLU 2nd to Drugs,OD,Moderate Stage
+9 ;;^UTILITY(U,$J,358.3,13240,1,4,0)
+10 ;;=4^H40.61X2
+11 ;;^UTILITY(U,$J,358.3,13240,2)
+12 ;;=^5005908
+13 ;;^UTILITY(U,$J,358.3,13241,0)
+14 ;;=H40.61X3^^51^632^50
+15 ;;^UTILITY(U,$J,358.3,13241,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,13241,1,3,0)
+18 ;;=3^GLU 2nd to Drugs,OD,Severe Stage
+19 ;;^UTILITY(U,$J,358.3,13241,1,4,0)
+20 ;;=4^H40.61X3
+21 ;;^UTILITY(U,$J,358.3,13241,2)
+22 ;;=^5133509
+23 ;;^UTILITY(U,$J,358.3,13242,0)
+24 ;;=H40.61X4^^51^632^51
+25 ;;^UTILITY(U,$J,358.3,13242,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,13242,1,3,0)
+28 ;;=3^GLU 2nd to Drugs,OD,Indeterminate Stage
+29 ;;^UTILITY(U,$J,358.3,13242,1,4,0)
+30 ;;=4^H40.61X4
+31 ;;^UTILITY(U,$J,358.3,13242,2)
+32 ;;=^5005909
+33 ;;^UTILITY(U,$J,358.3,13243,0)
+34 ;;=H40.813^^51^632^64
+35 ;;^UTILITY(U,$J,358.3,13243,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,13243,1,3,0)
+38 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OU
+39 ;;^UTILITY(U,$J,358.3,13243,1,4,0)
+40 ;;=4^H40.813
+41 ;;^UTILITY(U,$J,358.3,13243,2)
+42 ;;=^5005921
+43 ;;^UTILITY(U,$J,358.3,13244,0)
+44 ;;=H40.811^^51^632^62
+45 ;;^UTILITY(U,$J,358.3,13244,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,13244,1,3,0)
+48 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OD
+49 ;;^UTILITY(U,$J,358.3,13244,1,4,0)
+50 ;;=4^H40.811
+51 ;;^UTILITY(U,$J,358.3,13244,2)
+52 ;;=^5005919
+53 ;;^UTILITY(U,$J,358.3,13245,0)
+54 ;;=H40.812^^51^632^63
+55 ;;^UTILITY(U,$J,358.3,13245,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,13245,1,3,0)
+58 ;;=3^GLC w/ Increased Episcleral Venous Pressure,OS
+59 ;;^UTILITY(U,$J,358.3,13245,1,4,0)
+60 ;;=4^H40.812
+61 ;;^UTILITY(U,$J,358.3,13245,2)
+62 ;;=^5005920
+63 ;;^UTILITY(U,$J,358.3,13246,0)
+64 ;;=H40.823^^51^632^67
+65 ;;^UTILITY(U,$J,358.3,13246,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,13246,1,3,0)
+68 ;;=3^Hypersecretion GLC,OU
+69 ;;^UTILITY(U,$J,358.3,13246,1,4,0)
+70 ;;=4^H40.823
+71 ;;^UTILITY(U,$J,358.3,13246,2)
+72 ;;=^5005925
+73 ;;^UTILITY(U,$J,358.3,13247,0)
+74 ;;=H40.821^^51^632^65
+75 ;;^UTILITY(U,$J,358.3,13247,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,13247,1,3,0)
+78 ;;=3^Hypersecretion GLC,OD
+79 ;;^UTILITY(U,$J,358.3,13247,1,4,0)
+80 ;;=4^H40.821
+81 ;;^UTILITY(U,$J,358.3,13247,2)
+82 ;;=^5005923
+83 ;;^UTILITY(U,$J,358.3,13248,0)
+84 ;;=H40.822^^51^632^66
+85 ;;^UTILITY(U,$J,358.3,13248,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,13248,1,3,0)
+88 ;;=3^Hypersecretion GLC,OS
+89 ;;^UTILITY(U,$J,358.3,13248,1,4,0)
+90 ;;=4^H40.822
+91 ;;^UTILITY(U,$J,358.3,13248,2)
+92 ;;=^5005924
+93 ;;^UTILITY(U,$J,358.3,13249,0)
+94 ;;=H40.43X0^^51^632^27
+95 ;;^UTILITY(U,$J,358.3,13249,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,13249,1,3,0)
+98 ;;=3^Inflam GLC,OU,Stage Unspec
+99 ;;^UTILITY(U,$J,358.3,13249,1,4,0)
+100 ;;=4^H40.43X0
+101 ;;^UTILITY(U,$J,358.3,13249,2)
+102 ;;=^5005878
+103 ;;^UTILITY(U,$J,358.3,13250,0)
+104 ;;=H40.43X1^^51^632^28
+105 ;;^UTILITY(U,$J,358.3,13250,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,13250,1,3,0)
+108 ;;=3^Inflam GLC,OU,Mild Stage
+109 ;;^UTILITY(U,$J,358.3,13250,1,4,0)
+110 ;;=4^H40.43X1
+111 ;;^UTILITY(U,$J,358.3,13250,2)
+112 ;;=^5005879
+113 ;;^UTILITY(U,$J,358.3,13251,0)
+114 ;;=H40.43X2^^51^632^29
+115 ;;^UTILITY(U,$J,358.3,13251,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,13251,1,3,0)
+118 ;;=3^Inflam GLC,OU,Moderate Stage
+119 ;;^UTILITY(U,$J,358.3,13251,1,4,0)
+120 ;;=4^H40.43X2
+121 ;;^UTILITY(U,$J,358.3,13251,2)
+122 ;;=^5005880
